Efficacy and safety of canakinumab in adolescents and adults with colchicine-resistant familial Mediterranean fever

Arthritis Research & Therapy
Ahmet GülSerhan Sevgi

Abstract

This open-label pilot study aimed to investigate the efficacy of canakinumab in colchicine-resistant familial Mediterranean fever (FMF) patients. Patients with one or more attacks in a month in the preceding 3 months despite colchicine were eligible to enter a 30-day run-in period. Patients who had an attack during the first run-in period advanced to a second 30-day period. At the first attack, patients started to receive three canakinumab 150 mg subcutaneous injections at 4-week intervals, and were then followed for an additional 2 months. Primary efficacy outcome measure was the proportion of patients with 50 % or more reduction in attack frequency. Secondary outcome measures included time to next attack following last canakinumab dose and changes in quality of life assessed by SF-36. Thirteen patients were enrolled in the run-in period and 9 advanced to the treatment period. All 9 patients achieved a 50 % or more reduction in attack frequency, and only one patient had an attack during the treatment period. C-reactive protein and serum amyloid A protein levels remained low throughout the treatment period. Significant improvement was observed in both physical and mental component scores of the Short Form-36 at Day 8. Five pati...Continue Reading

References

Feb 1, 1991·Seminars in Arthritis and Rheumatism·E Ben-Chetrit, M Levy
Apr 17, 1986·The New England Journal of Medicine·D ZemerJ Gafni
Oct 31, 1974·The New England Journal of Medicine·D ZemerJ Gafni
Oct 31, 1974·The New England Journal of Medicine·C A DinarelloD W Alling
Oct 23, 1997·Arthritis and Rheumatism·A LivnehM Pras
Mar 21, 1998·Lancet·E Ben-Chetrit, M Levy
Mar 24, 2009·Annual Review of Immunology·Seth L MastersDaniel L Kastner
Jun 6, 2009·The New England Journal of Medicine·Helen J LachmannUNKNOWN Canakinumab in CAPS Study Group
Feb 1, 2011·Seminars in Arthritis and Rheumatism·Ulrich MeinzerIsabelle Koné-Paut
Aug 14, 2012·Autoimmunity Reviews·Merav LidarElon Pras
Oct 17, 2012·Annals of Internal Medicine·Philip J HashkesDaniel J Lovell
Dec 21, 2012·The New England Journal of Medicine·Nicolino RupertoUNKNOWN PRCSG
Jan 17, 2013·Clinical Reviews in Allergy & Immunology·Alessandra SorianoRaffaele Manna

❮ Previous
Next ❯

Citations

May 18, 2016·International Journal of Molecular Sciences·Lorna CampbellAli D Askari
Sep 8, 2016·Expert Opinion on Biological Therapy·Ruby Haviv, Philip J Hashkes
Jan 10, 2017·Expert Review of Clinical Immunology·Donato Rigante
Apr 8, 2017·International Immunology·Hafize Emine Sönmez, Seza Özen
Mar 18, 2017·Orphanet Journal of Rare Diseases·Alice CorsiaIsabelle Koné-Paut
Jun 19, 2017·Clinical Rheumatology·Mansour Alghamdi
Feb 17, 2018·Rheumatology International·Fatma YazılıtaşMehmet Bülbül
May 17, 2018·The New England Journal of Medicine·Fabrizio De BenedettiGuido Junge
Jan 4, 2017·The Journal of Rheumatology·Katerina LaskariPetros P Sfikakis
Jun 11, 2016·Current Opinion in Rheumatology·Shai Padeh, Yackov Berkun
Mar 6, 2018·Medicine·Kensuke AsakuraTakayuki Matsumoto
Sep 6, 2019·Nature Reviews. Rheumatology·Arlene Bravo, Arthur Kavanaugh
Jan 24, 2016·Annals of the Rheumatic Diseases·Seza OzenLoreto Carmona
Feb 14, 2017·Frontiers in Immunology·Carlos de Torre-MinguelaPablo Pelegrín
Aug 23, 2017·Rheumatology International·Kenan BarutOzgur Kasapcopur
Apr 20, 2019·International Journal of Molecular Sciences·Alessandra BettiolFlorenzo Iannone
Oct 17, 2019·Orphanet Journal of Rare Diseases·Georges El HasbaniImad Uthman
Aug 30, 2019·Paediatric Drugs·Rabia Miray Kisla EkinciMustafa Yilmaz
Jul 17, 2020·Frontiers in Immunology·Véronique HentgenSophie Georgin-Lavialle
May 18, 2018·Clinical Rheumatology·Jurgen SotaUNKNOWN “Working Group” of Systemic Autoinflammatory Diseases of SIR (Italian Society of Rheumatology)
Jun 24, 2019·Rheumatology International·Rotem TalLiora Harel
Sep 4, 2016·Molecular and Cellular Pediatrics·Betul SozeriErkin Serdaroglu
Apr 1, 2017·Expert Review of Clinical Immunology·Huri Ozdogan, Serdal Ugurlu
Jun 8, 2017·Frontiers in Pharmacology·Gabriele FeniniLars E French
Feb 22, 2018·Current Allergy and Asthma Reports·Iris M OtaniAleena Banerji
Jan 4, 2019·Rheumatology International·Amra Adrovic, Ozgur Kasapcopur
Oct 15, 2020·Rheumatology·Matthew A BrownZhixiu Li
Jun 4, 2021·Italian Journal of Pediatrics·Maria Francesca GicchinoAlma Nunzia Olivieri

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.